Psoriatic Disease Tied to Elevated APS Incidence: Study

KEY TAKEAWAYS

• New retrospective research found a 71% higher antiphospholipid syndrome (APS) risk in patients with psoriasis.

• The risk was elevated for those with psoriatic arthritis, older age, or comorbidities.

Data from a new cohort study has identified an increased risk of antiphospholipid syndrome (APS) in patients with psoriasis, particularly those with psoriatic arthritis (PsA).

Researchers for the study matched 288,678 patients from the TriNetX US Collaborative Networks (2002–2022) with psoriasis to an equal number of non-psoriasis patients. They then analyzed the incidence of APS using Cox proportional hazard models.

According to the results, individuals with psoriasis had a 71% higher risk of developing APS (HR = 1.71; 95% CI: 1.56 to 1.88), while patients with PsA faced an even greater risk (HR = 1.91; 95% CI: 1.58 to 2.31). Risk was elevated among older adults, females, Black or African American individuals and also in those with chronic comorbidities including diabetes, cerebrovascular disease, and depressive disorders.

“This is the first study to investigate the risk of APS in patients with psoriatic diseases,” the authors wrote. “Our results highlight the need for personalized screening and management strategies for patients with psoriasis at the greatest risk for comorbid conditions,” the researchers concluded. 

Source: Wang Q, et al. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1620768